Expression profiling for bladder cancer: Strategies to uncover prognostic factors

Georg Bartsch; Anirban P. Mitra; Richard J. Cote

doi:10.1586/era.10.131

Expression profiling for bladder cancer: Strategies to uncover prognostic factors

Georg Bartsch, Anirban P. Mitra, Richard J. Cote

Research output: Contribution to journal › Review article › peer-review

21 Scopus citations

Abstract

Despite being a common cancer worldwide, management of transitional cell carcinoma of the bladder currently relies primarily on clinical staging and histopathologic parameters. Assaying alterations in molecular pathways can contribute valuable information that can accurately predict outcome and chemotherapeutic response in individual patients with bladder cancer. Medium-to high-throughput gene-expression profiling technologies are now allowing multiplexed assessment of alterations responsible for the genesis and progression of bladder tumors. These investigations employ global or pathway-based approaches to define molecular signatures that can predict prognosis independent of traditional clinical performance metrics. Prognostic panels generated using these strategies can also elucidate the biology of tumor progression and identify potential therapeutic targets.

Original language	English
Pages (from-to)	1945-1954
Number of pages	10
Journal	Expert Review of Anticancer Therapy
Volume	10
Issue number	12
DOIs	https://doi.org/10.1586/era.10.131
State	Published - Dec 2010

Keywords

gene-expression profiling
global approach
microarray
multimarker analysis
pathway-specific approach
urothelial carcinoma

Access to Document

10.1586/era.10.131

Cite this

@article{2e04819b8a704197b28adc8469b67fcf,

title = "Expression profiling for bladder cancer: Strategies to uncover prognostic factors",

abstract = "Despite being a common cancer worldwide, management of transitional cell carcinoma of the bladder currently relies primarily on clinical staging and histopathologic parameters. Assaying alterations in molecular pathways can contribute valuable information that can accurately predict outcome and chemotherapeutic response in individual patients with bladder cancer. Medium-to high-throughput gene-expression profiling technologies are now allowing multiplexed assessment of alterations responsible for the genesis and progression of bladder tumors. These investigations employ global or pathway-based approaches to define molecular signatures that can predict prognosis independent of traditional clinical performance metrics. Prognostic panels generated using these strategies can also elucidate the biology of tumor progression and identify potential therapeutic targets.",

keywords = "gene-expression profiling, global approach, microarray, multimarker analysis, pathway-specific approach, urothelial carcinoma",

author = "Georg Bartsch and Mitra, {Anirban P.} and Cote, {Richard J.}",

note = "Funding Information: Studies described in this article were supported in part by NIH Grants CA-70903, CA-14089, CA-86871 and CA-103455, and National Cancer Institute Grant CA-71921. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",

year = "2010",

month = dec,

doi = "10.1586/era.10.131",

language = "English",

volume = "10",

pages = "1945--1954",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

number = "12",

}

TY - JOUR

T1 - Expression profiling for bladder cancer

T2 - Strategies to uncover prognostic factors

AU - Bartsch, Georg

AU - Mitra, Anirban P.

AU - Cote, Richard J.

N1 - Funding Information: Studies described in this article were supported in part by NIH Grants CA-70903, CA-14089, CA-86871 and CA-103455, and National Cancer Institute Grant CA-71921. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

PY - 2010/12

Y1 - 2010/12

N2 - Despite being a common cancer worldwide, management of transitional cell carcinoma of the bladder currently relies primarily on clinical staging and histopathologic parameters. Assaying alterations in molecular pathways can contribute valuable information that can accurately predict outcome and chemotherapeutic response in individual patients with bladder cancer. Medium-to high-throughput gene-expression profiling technologies are now allowing multiplexed assessment of alterations responsible for the genesis and progression of bladder tumors. These investigations employ global or pathway-based approaches to define molecular signatures that can predict prognosis independent of traditional clinical performance metrics. Prognostic panels generated using these strategies can also elucidate the biology of tumor progression and identify potential therapeutic targets.

AB - Despite being a common cancer worldwide, management of transitional cell carcinoma of the bladder currently relies primarily on clinical staging and histopathologic parameters. Assaying alterations in molecular pathways can contribute valuable information that can accurately predict outcome and chemotherapeutic response in individual patients with bladder cancer. Medium-to high-throughput gene-expression profiling technologies are now allowing multiplexed assessment of alterations responsible for the genesis and progression of bladder tumors. These investigations employ global or pathway-based approaches to define molecular signatures that can predict prognosis independent of traditional clinical performance metrics. Prognostic panels generated using these strategies can also elucidate the biology of tumor progression and identify potential therapeutic targets.

KW - gene-expression profiling

KW - global approach

KW - microarray

KW - multimarker analysis

KW - pathway-specific approach

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=78649676657&partnerID=8YFLogxK

U2 - 10.1586/era.10.131

DO - 10.1586/era.10.131

M3 - Review article

C2 - 21110760

AN - SCOPUS:78649676657

SN - 1473-7140

VL - 10

SP - 1945

EP - 1954

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 12

ER -

Expression profiling for bladder cancer: Strategies to uncover prognostic factors

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this